LDL — research review 2

...and this is why, when we talk about longevity interventions, we really need to focus on human clinical trial data. So many headlines spring from cell studies or animal models, which just don't always translate.

Exactly. The human evidence is the gold standard. Take LDL cholesterol, for example – often called "bad" cholesterol. We have decades of robust data showing its impact on cardiovascular health.

Right. And for longevity, cardiovascular health is paramount. High LDL is a major risk factor for heart disease, which is a leading cause of death globally. We see this consistently across large population studies.

And importantly, interventions that lower LDL, like statins, have been extensively studied in humans. A meta-analysis published in The Lancet in 2019, for instance, combined data from over 170,000 participants and found significant reductions in major cardiovascular events with statin therapy.

That’s the kind of evidence we’re looking for – clear, human-based outcomes. But it's also crucial to highlight when the evidence isn't there, or when trials show null results. For many of the newer, more speculative longevity compounds, we just don't have that robust human trial data for long-term healthy aging outcomes yet.

Precisely. We know lowering LDL reduces cardiovascular risk and that contributes to a longer, healthier life. But for many other proposed longevity supplements, while some might show promise in early studies, direct human evidence demonstrating increased healthy lifespan or reduced all-cause mortality is still largely unproven. The hype often outpaces the evidence.

Which means the default should always be: show me the human data.